Pemvidutide (Altimmune): The GLP-1 + Glucagon Drug Explained

The different mechanism: why glucagon matters

Most next-gen obesity drugs stack GLP-1 with GIP (tirzepatide) or amylin (amycretin, CagriSema). Pemvidutide takes a different route: GLP-1 + glucagon. Glucagon is usually thought of as a blood-sugar-raising hormone, but at the right receptor balance it increases energy expenditure and — critically — directly reduces liver fat. That makes pemvidutide a two-indication bet: obesity and MASH (metabolic dysfunction-associated steatohepatitis, the serious form of fatty liver).

What the trials showed

• MOMENTUM (obesity, Phase 2): up to ~15.6% weight loss at 48 weeks — semaglutide-range efficacy.
• Liver fat: trials showed reductions of 50%+ in liver fat content in many participants — among the strongest reported for the class.
• Lean mass: reported composition data suggested a better fat-to-lean loss ratio than typical GLP-1s — potentially relevant for older adults and anyone worried about GLP-1 muscle loss.
• Side effects: GI-dominant (nausea, vomiting), consistent with the class.

Where it fits vs. approved drugs

See our semaglutide for MASH guide for the only GLP-1 already FDA-approved for fatty liver.

Should you wait for it?

No — and that applies to every pipeline drug. If you have obesity and especially fatty liver disease, the metabolic damage compounds while trials run. Semaglutide already carries a MASH indication and delivers equivalent weight loss; tirzepatide delivers more. If pemvidutide's liver-specific profile proves out in Phase 3, it will still be there in 2028 — with more data.

Frequently asked questions

What is pemvidutide?

Pemvidutide is Altimmune's experimental once-weekly injection — a dual agonist of the GLP-1 receptor (appetite suppression) and the glucagon receptor (energy expenditure and liver fat reduction). The glucagon component is what makes it especially interesting for fatty liver disease (MASH).

How much weight does pemvidutide help you lose?

The Phase 2 MOMENTUM trial showed up to ~15.6% weight loss at 48 weeks — in the same range as semaglutide, though below tirzepatide. What stands out: lean mass preservation data suggested a smaller fraction of weight lost was muscle than typical GLP-1s.

Does pemvidutide help fatty liver disease?

That's a key part of its design. Glucagon receptor activation directly reduces liver fat — pemvidutide trials showed large reductions in liver fat content, which is why Altimmune is pursuing it in MASH alongside obesity.

Is pemvidutide approved?

No — it is investigational, in Phase 3 development for MASH and earlier obesity data. Realistic approval is 2028 or later. It cannot be prescribed or legally purchased anywhere.

What treats fatty liver and weight today?

Semaglutide is FDA-approved for MASH (as Wegovy's expanded indication) and resmetirom (Rezdiffra) is approved for MASH fibrosis. For weight loss, compounded semaglutide via licensed telehealth starts at $119/month.

Bottom line

Pemvidutide's GLP-1 + glucagon pairing is genuinely differentiated — strong liver fat data and possibly kinder lean-mass loss. But it's years from market, and the condition it targets is already treatable: semaglutide programs from $119/month address both weight and liver fat today.